IP Library Granted Patent US 7,381,560
Granted Patent B2
US 7,381,560 · App. 09/911,692 · Granted Jun 3, 2008

Expression and use of anti-CD20 antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,381,560
App. No.
09/911,692
Granted
Jun 3, 2008
Kind
B2
Abstract

Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody and methods of using such host cells to make purified antibodies. The antibodies are useful for treating and diagnosing B cell disorders.

Claims (10)

1. A host cell comprising nucleic acid sequences encoding the light chain and the heavy chain of an immunologically active chimeric anti-CD20 antibody, wherein the sequence encoding the light chain comprises a nucleotide sequence encoding amino acid residues 23 to 128 of SEQ ID NO: 4, and the sequence encoding the heavy chain comprises a nucleotide sequence encoding amino acid residues 20 to 140 of SEQ ID NO: 6, wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody.

2. The host cell of claim 1 wherein the sequence encoding the light chain further comprises a nucleotide sequence encoding a human kappa light chain constant region, and the sequence encoding the heavy chain further comprises a nucleotide sequence encoding a human gamma 1 heavy chain constant region.

3. A method of making a purified antibody comprising expressing the light and heavy chains encoded by the nucleic acid sequences in the host cell of claim 1 and purifying the antibody produced by the host cell.

4. The method of claim 3 further comprising combining the purified antibody with a pharmaceutically acceptable buffer.

5. The method of claim 3 further comprising combining the purified antibody with a pharmaceutical carrier.

6. The host cell of claim 1 , wherein the host cell comprises an expression vector or separate expression vectors comprising the nucleic acid sequences encoding the light chain and the heavy chain.

7. The host cell of claim 1 , wherein the host cell comprises an expression plasmid or separate expression plasmids comprising the nucleic acid sequences encoding the light chain and the heavy chain.

8. The host cell of claim 1 which is a mammalian cell.

9. The host cell of claim 1 which is a Chinese Hamster Ovary (CHO) cell.

10. The host cell of claim 1 which is an SP2/0 cell.

Assignments (4)
CHANGE OF NAME Recorded Apr 30, 2015
From: BIOGEN IDEC INC.
To: BIOGEN INC.
Reel/Frame 035552/0202 →
CHANGE OF NAME Recorded Mar 18, 2008
From: IDEC PHARMACEUTICALS CORP.
To: BIOGEN IDEC INC.
Reel/Frame 020667/0643 →
MERGER Recorded Feb 12, 2008
From: IDEC PHARMACEUTICALS CORP. (CALIFORNIA)
To: IDEC PHARMACEUTICALS CORP. (DELAWARE)
Reel/Frame 020498/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2001
From: ANDERSON, DARRELL R.; HANNA, NABIL; LEONARD, JOHN E.; NEWMAN, ROLAND A.; REFF, MITCHELL E.; RASTETTER, WILLIAM H.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 012297/0365 →